Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: An interinstitutional study

Medical and Pediatric Oncology

Volumn 40, Issue 5, 2003, Pages 302-308

  Camassei, Francesca Diomedi ^a   Jenkner, Alessandro ^a   Ravà, Lucilla ^a   Bosman, Cesare ^b   Francalanci, Paola ^a   Donfrancesco, Alberto ^a   Alò, Piero L ^b   Boldrini, Renata ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Fatty acid synthase; Favorable histology; Immunohistochemistry; Nephroblastoma; Prognosis

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; FATTY ACID SYNTHASE; VINCRISTINE;

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER GRADING; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE COURSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHRECTOMY; NEPHROBLASTOMA; OUTCOMES RESEARCH; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 0037403024     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10274     Document Type: Article

References (28)

1. Murphy WM, Beckwith JB, Farrow GM. Tumors in infancy and childhood. In: Tumors of the kidney, bladder and related urinary structures. Washington D.C.: AFIP; 1994. (3° series), fascicle 11:12-92.
2. Wiener JS, Coppes MJ, Ritchey ML. Current concepts in the biology and management of Wilms tumor. J Urol 1998;159:1316-1325.
3. Nephroblastoma Clinical Trial. n° 93-01, Protocol, June 1993. (revised December 1995).
4. Kuhajda FP. Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition 2000;16:202-208.
5. 2 to functional genomics. Biochem Soc Trans 2000;28: 567-573.
6. Latasa MJ, Moon YS, Kim KH, et al. Nutritional regulation of the fatty acid synthase promoter in vivo: Sterol regulatory element binding protein functions through an upstream region containing a sterol regulatory element. Proc Natl Acad Sci USA 2000;97: 10619-10624.
7. Weiss L, Hoffman G, Schreiber R, et al. Fatty-acid biosythesis in man, a pathway of minor importance. Biol Chem 1986;367:905-912.
8. Kusakabe T, Maeda M, Hoshi N, et al. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem 2000;48:613-622.
9. Wilentz RE, Witters LA, Pizer ES. Lipogenic enzymes fatty acid synthase and acetyl-coenzyme A carboxylase are coexpressed with sterol regulatory element binding protein and Ki-67 in fetal tissues. Pediatr Dev Pathol 2000;3:525-531.
10. Alò PL, Visca P, Marci A, et al. Expression of fatty acic synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996;77:474-482.
11. Alò PL, Visca P, Trombetta G, et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 1999;85:35-40.
12. Milgraum LZ, Witters LA, Pasternack GR, et al. Enzymes of the fatty acid pathways are highly expressed in in situ breast cancer. Clin Cancer Res 1997;3:2115-2120.
13. Shurbaji MS, Kuhajda FP, Pasternack GR, et al. Immunohistochemical detection of a fatty acic synthase (OA-519) as a predictor of progression in prostate cancer. Hum Pathol 1996; 27:917-921.
14. Myers RB, Oelschlager DK, Weiss HL, et al. Fatty acid synthase: An early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 2001;165:1027-1032.
15. Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000;88:176-179.
16. Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997;150:201-208.
17. Pizer ES, Lax S, Kuhajda FP, et al. Fatty acid synthase expression in endometrial carcinoma: Correlation with cell proliferation and hormone receptors. Cancer 1998;83:528-537.
18. Gansler TS, Hardman W, Hunt DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686-692.
19. Alò PL, Visca P, Framarino ML, et al. Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 2000;7: 1383-1388.
20. Vlad LD, Axiots CA, Merino MJ, et al. Fatty acid synthase is highly expressed in aggressive thyroid tumors. Mod Pathol 1999;12: 70A.
21. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000;31:1068-1073.
22. Suryanarayan K, Marina N. Wilms tumour. Optimal treatment strategies. Drugs 1998;56:597-605.
23. Kuhajda FP, Pizer ES, Li JN, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000; 97:3450-3454.
24. Pizer ES, Wood FD, Heine HS, et al. Inhibition of fatty acid synthase delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996;56:1189-1193.
25. Pizer ES, Chrest FJ, Di Giuseppe JA, et al. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replcation and induce apoptosis in tumor cell lines. Cancer Res 1998;58:4611-4615.
26. Furuya Y, Akimoto S, Yasada K, et al. Apoptosis of androgen-indipendent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res 1997;17:4589-4593.
27. Pizer ES, Jackisch C, Wood FD, et al. Inhibition of fatty acid synthase induces programmed cell death in human breast cancer cells. Cancer Res 1996;56:2745-2747.
28. Gabrielson EW, Pinn ML, Testa JR, et al. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 2001;7:153-157.